Bi-specific T-cell engager antibodies (BiTEs) are synthetic fusion molecules that combine multiple antibody-binding domains to induce active contact between T-cells and antigen expressing cells in the body. Blinatumomab. a CD19-CD3 BiTE is now a widely used therapy for relapsed B-cell malignancies. and similar BiTE therapeutics have shown promise for treating various other forms of ca... https://www.bekindtopets.com/deal-find-Equi-Jec-6-best-super/